导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 2.45% | 1635/4773 |
| 近一周 | -1.92% | 890/5462 |
| 近一月 | -3.66% | 1892/5421 |
| 近一季 | -6.11% | 1990/5209 |
| 近半年 | 1.04% | 1089/4920 |
| 近一年 | 4.38% | 1732/4366 |
| 近两年 | 47.90% | 1540/2954 |
| 近三年 | 33.61% | 911/2253 |
| 成立以来 | 55.31% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-2.49% 2803/4961 |
15.64% 1647/5312 |
- - |
- - |
| 2025 | 20.88% 2075/4813 |
-0.29% 2185/3635 |
2.38% 1606/4076 |
19.00% 2209/4524 |
-0.49% 2517/4813 |
| 2024 | 14.81% 1001/3463 |
4.59% 445/2808 |
0.13% 647/3014 |
13.21% 2218/3129 |
-3.17% 2279/3463 |
| 2023 | -7.15% 894/2656 |
3.41% 1365/3759 |
-2.37% 1274/3909 |
-2.63% 708/4055 |
-5.54% 2335/4209 |
| 2022 | -21.67% 1390/3578 |
-13.79% 657/2804 |
5.96% 1817/3205 |
-13.10% 1865/3430 |
-1.32% 1817/3570 |
| 2021 | 1.78% 911/2717 |
-2.33% 665/1745 |
7.53% 1179/2232 |
-2.27% 886/2560 |
-0.84% 1686/2708 |
| 2020 | 46.26% 658/1596 |
-3.62% 650/1036 |
17.16% 811/1256 |
15.05% 328/1472 |
12.59% 839/1690 |
| 2019 | 40.29% 405/926 |
18.29% 1508/3053 |
0.30% 1227/3201 |
10.60% 205/939 |
6.91% 660/1014 |
| 2018 | -27.56% 374/668 |
- - |
-7.45% 2135/2983 |
-3.18% 1484/2970 |
-11.69% 2283/2975 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 中银沪深300指数增强A VS. 长安沪深300非周期A(740101) |